Solventum Corporation filed its Form 10-Q with the Securities and Exchange Commission on November 5, 2026, covering the quarterly period ended September 30, 2026, disclosing a net loss of $12 million on total net sales of $1.949 billion for the third quarter.
Key Highlights
- Total net sales: $1.949 billion for the three months ended September 30, 2026, compared to $2.096 billion in the same period of 2025, according to the filing.
- Net loss: $(12) million for Q3 2026, versus net income of $1.266 billion in Q3 2025, which the filing notes included a $1.518 billion gain on sale of business.
- Basic and diluted EPS: $(0.07) per share for Q3 2026, compared to $7.26 basic and $7.22 diluted in Q3 2025.
- Nine-month net income: $93 million on total net sales of $6.165 billion for the nine months ended September 30, 2026.
- Total assets: $14.165 billion as of September 30, 2026, with total equity of $4.805 billion.
- Treasury stock: The company reported 5,346,853 shares held in treasury at a cost of $403 million as of September 30, 2026, compared to zero treasury shares at December 31, 2025.
- Shares outstanding: 169,739,335 shares of common stock outstanding as of October 31, 2026, the filing disclosed.
Solventum's Third-Quarter 2026 Financial Results: Product and Software Sales Decline Year Over Year
Solventum Corporation, a Delaware-incorporated healthcare technology company headquartered in Eagan, Minnesota, trading on NYSE:SOLV, reported total net sales of $1.949 billion for the three months ended September 30, 2026. According to the filing, net sales of product were $1.431 billion and net sales of software and rentals were $518 million, compared to $1.594 billion and $502 million, respectively, in the third quarter of 2025. Gross profit for the quarter was $1.062 billion, down from $1.135 billion a year earlier.
The filing disclosed that selling, general and administrative expenses increased to $813 million in Q3 2026 from $780 million in Q3 2025, while research and development expenses were $181 million, compared to $183 million in the prior-year period. Operating income for the quarter was $68 million, against $1.690 billion in Q3 2025. The prior-year quarter included a $1.518 billion gain on sale of business that did not recur in 2026, according to the filing. Interest expense, net, was $68 million for Q3 2026, compared to $89 million in Q3 2025.
For the nine months ended September 30, 2026, the company reported total net sales of $6.165 billion and net income of $93 million, or $0.54 per basic and diluted share. The filing showed total assets of $14.165 billion at September 30, 2026, with goodwill of $5.616 billion and intangible assets, net, of $2.317 billion. Cash and cash equivalents stood at $451 million, down from $878 million at December 31, 2025. Long-term debt was $4.561 billion, and a new finance lease liability of $206 million appeared on the balance sheet, which carried no such balance at December 31, 2025. The company also initiated a share repurchase program during the period, accumulating 5,346,853 treasury shares at a cost of $403 million by September 30, 2026.
What Was Disclosed
Solventum's 10-Q for the quarter ended September 30, 2026 reported a net loss of $12 million on $1.949 billion in total net sales, with nine-month net income of $93 million. The filing also disclosed initiation of treasury stock purchases totaling $403 million and total assets of $14.165 billion.




Please wait processing your request...